These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2100158)

  • 1. Nonclinical study requirements for ophthalmic drugs and devices in the United States.
    Hackett RB
    Lens Eye Toxic Res; 1990; 7(3-4):181-205. PubMed ID: 2100158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Requirements of preclinical examinations.
    Lehnert T; Ulbrich B
    Lens Eye Toxic Res; 1990; 7(3-4):207-19. PubMed ID: 2100159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of moxifloxacin as shown in animal and in vitro studies.
    McGee DH; Holt WF; Kastner PR; Rice RL
    Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S46-54. PubMed ID: 16257310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contact lens safety and the FDA: 1976 to the present.
    Saviola JF
    Eye Contact Lens; 2007 Nov; 33(6 Pt 2):404-9; discussion 410-1. PubMed ID: 17975433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Criteria supporting the study of drugs in the newborn.
    Ward RM; Benitz WE; Benjamin DK; Blackmon L; Giacoia GP; Hudak M; Lasky T; Rodriguez W; Selen A
    Clin Ther; 2006 Sep; 28(9):1385-98. PubMed ID: 17062311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Food and Drug Administration approval process for ophthalmic drugs in the US.
    Lloyd R; Harris J; Wadhwa S; Chambers W
    Curr Opin Ophthalmol; 2008 May; 19(3):190-4. PubMed ID: 18408492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ocular and systemic adverse effects of ophthalmic and non ophthalmic medications.
    Izazola-Conde C; Zamora-de la Cruz D; Tenorio-Guajardo G
    Proc West Pharmacol Soc; 2011; 54():69-72. PubMed ID: 22423585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory immunotoxicology: does the published evidence support mandatory nonclinical immune function screening in drug development?
    Snodin DJ
    Regul Toxicol Pharmacol; 2004 Dec; 40(3):336-55. PubMed ID: 15546688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocular preservatives: associated risks and newer options.
    Kaur IP; Lal S; Rana C; Kakkar S; Singh H
    Cutan Ocul Toxicol; 2009; 28(3):93-103. PubMed ID: 19505226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The current requirements for the preclinical study of the safety of new drugs].
    Arzamastsev EV; Liubimov BI
    Eksp Klin Farmakol; 1995; 58(3):7-12. PubMed ID: 7663306
    [No Abstract]   [Full Text] [Related]  

  • 12. An FDA perspective on the nonclinical use of the X-Omics technologies and the safety of new drugs.
    Jacobs A
    Toxicol Lett; 2009 Apr; 186(1):32-5. PubMed ID: 18809476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reproductive toxicology guidelines: comparison and application.
    Beltrame D; Mazué G
    Ann Ist Super Sanita; 1993; 29(1):3-14. PubMed ID: 8129269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Status of toric intraocular lenses.
    Horn JD
    Curr Opin Ophthalmol; 2007 Feb; 18(1):58-61. PubMed ID: 17159449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A masked quantitative cytologic study of the safety of a multipurpose contact lens solution applied to the in vivo rabbit eye.
    Bergmanson JP; Ross RN
    J Am Optom Assoc; 1993 May; 64(5):308-14. PubMed ID: 8320413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of the Crystalens AT-45 accommodating intraocular lens: results of the U.S. Food and Drug Administration clinical trial.
    Cumming JS; Colvard DM; Dell SJ; Doane J; Fine IH; Hoffman RS; Packer M; Slade SG
    J Cataract Refract Surg; 2006 May; 32(5):812-25. PubMed ID: 16765800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A comparison of intraocular penetration of ocular drugs during the use of contact lenses and of various methods of topical administration. An experiment with radioactive sulfate].
    Krejcí L; Praus R; Brettschneider I
    Cesk Oftalmol; 1975 Nov; 31(6):423-9. PubMed ID: 1212694
    [No Abstract]   [Full Text] [Related]  

  • 18. The FDA report on intraocular lenses.
    Stark WJ; Worthen DM; Holladay JT; Bath PE; Jacobs ME; Murray GC; McGhee ET; Talbott MW; Shipp MD; Thomas NE
    Aust J Ophthalmol; 1984 Feb; 12(1):61-9. PubMed ID: 6547332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contact lenses for drug delivery.
    Ciolino JB; Dohlman CH; Kohane DS
    Semin Ophthalmol; 2009; 24(3):156-60. PubMed ID: 19437351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International Conference on Harmonisation: guidance on testing for carcinogenicity of pharmaceuticals. Notice. Food and Drug Administration, HHS.
    Fed Regist; 1998 Feb; 63(35):8983-6. PubMed ID: 12269370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.